Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PRICES OF 5,000 MOST PRESCRIBED DRUGS UP 9.1% IN 1989

Executive Summary

PRICES OF 5,000 MOST PRESCRIBED DRUGS UP 9.1% IN 1989, Medi-Span reports in its "1989 Inflation Report." The figure is in line with Bureau of Labor Statistics' Producer Price Index figures for the year that put prescription drug inflation at 9.7% ("The Pink Sheet" Jan. 22, p. 14). The PPI, however, is weighted for sales volume, while Medi-Span's data is not. Of the 5,000 prescription drugs followed by the pharmaceutical tracking firm, Medi-Span reported that 2,595 had price changes during the year. The average price increase for only those items that had price changes is substantially higher, at 14.6%. Price increases for the top 200 (most prescribed) prescription drug products, however, were only 5.5%. The top 200 products include a total of 568 items (or pack sizes), for which 329 had price changes during the year. The average price hike for the 329 items was 9.5%. Medi-Span data on 10,000 hospital drug products indicate that prices changed for 4,931 of the products during the year. The average price change for the 10,000 items was 7.2%, while the average increase for the 4,931 products with price changes was 8.1%. The firm's larger data base on approximately 59,000 prescription, OTC and drug sundries that were marketed throughout the year showed an overall price rise of 5%. Among those products, prices for single-source items rose 5.8%, while prices for multiple-source products rose 4.7%, Medi-Span reported.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017244

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel